Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06914895 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
A Phase 3 study of Obesity and Type 1 Diabetes, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 905
- Enrollment target
- 20
- Study locations
NCT06914895: Active Phase 3 study of Obesity and Type 1 Diabetes, sponsored by Eli Lilly and Company.
NCT06914895 is a Phase 3 study of Obesity and Type 1 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 905 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06914895, a Phase 3 study of Obesity and Type 1 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 905 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
Georgia
- Atlanta Diabetes Associates - Atlanta
- Orita Clinical Research - Decatur
- North Georgia Clinical Research - Woodstock
New York
- Albany Medical College, Division of Community Endocrinology - Albany
- Research Foundation of SUNY - University of Buffalo - Buffalo
- NYC Research - New York
California
- Sansum Diabetes Research Institute - Santa Barbara
- Care Access - Santa Clarita - Santa Clarita
Nevada
- Palm Research Center Tenaya - Las Vegas
- Palm Research Center Sunset - Las Vegas
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Hawaii
- East-West Medical Research Institute - Honolulu
Idaho
- Rocky Mountain Clinical Research - Idaho Falls
Illinois
- Southern Illinois University School of Medicine - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 905 participants |
| Start Date | 2025-04-25 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What the registry record for NCT06914895 still lists
NCT06914895 is an interventional study that assigns participants to a tested intervention. The registered 905 participants enrollment target is mid-sized for trials with a published cap, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (11% higher).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06914895 names 20 study sites across 14 states, led by Georgia, New York, California.
Frequently Asked Questions
What is clinical trial NCT06914895 about?
NCT06914895 is a clinical study titled "A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight". The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
What is the current status of trial NCT06914895?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 905 participants. The study started on 2025-04-25. Estimated completion is 2026-12.
What conditions does trial NCT06914895 study?
This clinical trial studies the following conditions: Obesity, Type 1 Diabetes, Overweight.
What interventions are being tested in trial NCT06914895?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06914895?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06914895 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Hawaii, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06914895's enrollment target sits among peer trials
905 81st of 1053 higher than 973 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI